Quanterix (NASDAQ:QTRX – Get Free Report) will likely be posting its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Quanterix to post earnings of ($0.4850) per share and revenue of $37.2060 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.
Quanterix (NASDAQ:QTRX – Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). The firm had revenue of $41.40 million during the quarter, compared to analyst estimates of $37.95 million. Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Quanterix Price Performance
QTRX traded up $0.05 during trading on Tuesday, reaching $3.42. 52,281 shares of the stock were exchanged, compared to its average volume of 780,564. The company has a market capitalization of $160.73 million, a price-to-earnings ratio of -1.35 and a beta of 1.16. Quanterix has a 1 year low of $2.95 and a 1 year high of $8.77. The business’s 50 day moving average price is $4.26 and its two-hundred day moving average price is $5.66.
Institutional Inflows and Outflows
Analyst Ratings Changes
QTRX has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Quanterix in a research note on Tuesday, April 21st. Canaccord Genuity Group decreased their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Finally, Wall Street Zen downgraded Quanterix from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $4.00.
Read Our Latest Stock Analysis on QTRX
Quanterix Company Profile
Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.
The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.
Featured Stories
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
